Table of Contents
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country-wise market estimation using bottom-up approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1:
1.11.2 Objective 2:
1.12 List of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Sustained Release Excipients Market Variables, Trends, & Scope
4.1 Sustained Release Excipients Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration and Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Increased Benefits Over Conventional Dosage Forms
4.4.2 Increased Acceptance Due To Nature Of Dosage Forms
4.4.3 Necessity Of Pediatric And Geriatric Sustained Release Dosage Forms
4.4.4 Antibiotic Resistance
4.5 Market Restraint Analysis
4.5.1 Drug Toxicity Due To Dose Dumping
4.5.2 Need For High Dose Of API
4.6 Market Challenge Analysis
4.6.1 Patient Education And Counselling
4.6.2 Higher Cost Of Sustained Release Systems In Comparison To Conventional Pharmaceutical Formulations
4.7 Key Opportunities
4.7.1 Minimization Of Hepatic First Pass Elimination
4.7.1 Development Cost-Efficient Dosage Forms
4.8 Sustained Release Excipients Market – PESTLE analysis
4.9 Industry Analysis – Porter’s
4.10 Major Deals and Strategic Alliances Analysis
4.10.1 Joint Ventures
4.10.2 Mergers And Acquisitions
4.10.3 Licensing And Partnership
4.10.4 Technology Collaborations
4.10.5 Strategic Divestments
4.11 Covid-19 Impact Analysis
Chapter 5 Sustained Release Excipients Market – Segment Analysis, By Product, 2018 – 2030 (USD Million)
5.1 Global Sustained Release Excipients Market: Product Movement Analysis
5.2 Gelatin
5.2.1 Gelatin Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.3 Polymers
5.3.1 Polymers Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.4 Minerals
5.4.1 Minerals Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.5 Sugars
5.5.1 Sugars Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.6 Alcohol
5.6.1 Alcohol Market Estimates And Forecast, 2018 – 2030 (USD Million)
5.7 Chitosan
5.7.1 Chitosan Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 6 Sustained Release Excipients Market- Segment Analysis, By Route Of Administration, 2018 – 2030 (USD Million)
6.1 Sustained Release Excipients Market: Route Of Administration Movement Analysis
6.2 Oral
6.2.1 Oral Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.3 Intramuscular
6.3.1 Intramuscular Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.4 Subcutaneous
6.4.1 Subcutaneous Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.5 Transdermal
6.5.1 Transdermal Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.6 Vaginal
6.6.1 Vaginal Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.6 Ophthalmic
6.6.1 Ophthalmic Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.7 Intravenous
6.7.1 Intravenous Market Estimates And Forecast, 2018 – 2030 (USD Million)
6.8 Others
6.8.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 7 Sustained Release Excipients Market – Segment Analysis, By Technology, 2018 – 2030 (USD Million)
7.1 Global Sustained Release Excipients Market: Technology Movement Analysis
7.2 Targeted Delivery
7.2.1 Targeted Delivery Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3 Microencapsulation
7.3.1 Microencapsulation Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4 Wurster Technique
7.4.1 Wurster Technique Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5 Transdermal
7.5.1 Transdermal Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6 Implants
7.6.1 Implants Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.7 Coacervation
7.7.1 Coacervation Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.8 Others
7.8.1 Others Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 8 Sustained Release Excipients Market: – Segment Analysis, by Region, 2018 – 2030 (USD Million)
8.1 Sustained Release Excipients Market: Regional Movement Analysis
8.2 North America
8.2.1 North America Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.2.3 Canada
8.2.3.1 Canada Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3.2 U.K.
8.3.2.1 U.K. Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3.3. Germany
8.3.3.1 Germany Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3.4 France
8.3.4.1 France Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3.5. Italy
8.3.5.1 Italy Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.3.5 Spain
8.3.5.1 Spain Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Asia Pacific Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.4.2 Japan
8.4.2.1 Japan Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.4.3 China
8.4.3.1 China Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.4.4 India
8.4.4.1 India Market Estimates And Forecast, 2018-2030
8.4.5 South Korea
8.4.5.1 South Korea Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.4.6 Australia
8.4.6.1 Australia Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.5 Latin America
8.5.1 Latin America Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.5.4 Argentina
8.5.4.1 Argentina Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.6 Middle East & Africa (MEA)
8.6.1 Middle East & Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 – 2030 (USD Million)
8.6.4 UAE
8.6.4.1 UAE Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 9 Competitive Landscape
9.1 Public Companies
9.1.1 Company Market Position Analysis
9.1.2 Competitive Dashboard Analysis
9.1.3 Strategic Framework
9.2 Private Companies
9.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
9.2.2 Regional Network Map
9.3 Company Profiles: Sustained Release Drugs
9.3.1 TEVA PHARMACEUTICAL INDUSTRIES LTD.
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 MYLAN N.V.
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 PFIZER, INC.
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 SUN PHARMACEUTICAL INDUSTRIES LTD.
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 NOVARTIS AG
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 ASTRAZENECA
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 GLAXOSMITHKLINE PLC
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 ALLERGAN PLC
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 JANSSEN PHARMACEUTICALS, INC.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 MAYNE PHARMA GROUP LIMITED
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
9.4 Company Profiles: Sustained Release Technology
9.4.1 Croda International Plc
9.4.1.1 Company Overview
9.4.1.2 Financial Performance
9.4.1.3 Product Benchmarking
9.4.1.4 Strategic Initiatives
9.4.2 Merck KGaA
9.4.2.1 Company Overview
9.4.2.2 Financial Performance
9.4.2.3 Product Benchmarking
9.4.2.4 Strategic Initiatives
9.4.3 BASF
9.4.3.1 Company Overview
9.4.3.2 Financial Performance
9.4.3.3 Product Benchmarking
9.4.3.4 Strategic Initiatives
9.4.4 Ashland Global
9.4.4.1 Company Overview
9.4.4.2 Financial Performance
9.4.4.3 Product Benchmarking
9.4.4.5 Strategic Initiatives
9.4.5 International Flavors & Fragrances, Inc.
9.4.5.1 Company Overview
9.4.5.2 Financial Performance
9.4.5.3 Product Benchmarking
9.4.5.4 Strategic Initiatives
9.4.6 Evonik Industries
9.4.6.1 Company Overview
9.4.6.2 Financial Performance
9.4.6.3 Product Benchmarking
9.4.6.4 Strategic Initiatives
9.5.7 Gattefossé
9.5.7.1 Company Overview
9.5.7.2 Financial Performance
9.5.7.3 Product Benchmarking
9.5.7.4 Strategic Initiatives